Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Nuvation Bio Inc.
NUVB
NYSE·Healthcare·Biotechnology·Mkt cap $1.9B
$5.70
▲ +5.17%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$2.01 - $9.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 164.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
1 reason
- High barriers to entry (70%+ gross margins)
Bear Case
2 risks
- Above-average volatility (beta 1.6).
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Moderate growth ahead
Strong revenue growth (699% YoY)
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+22.9% over 3m
Quality
Excellent
High-growth business (500% revenue growth, 92% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying NUVB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 4, 2026
Reported EPS of $0.01 vs -$0.03 consensus (+135.7% surprise). Revenue of $83.2M vs $66.2M expected (+25.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+135.7%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
—
—
+237%
+1705%
+633%
+2599%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.4M
$727.0K
$5.7M
$3.1M
$4.8M
$13.1M
$41.9M
$83.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
6.5%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: Citi · Jun 10, 2026